Shares of Charles River CRL moved higher by 0.1% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were down 3.07% year over year to $1.58, which beat the estimate of $1.26.
Revenue of $682,584,000 up by 3.80% year over year, which beat the estimate of $641,630,000.
Outlook
The upcoming fiscal year's EPS expected to be between $7.05 and $7.35.
The upcoming fiscal year's revenue expected to be between $2,817,575,000 and $2,857,000,000.
Details Of The Call
Date: Aug 05, 2020
Time: 09:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/4xv2t4mz
Recent Stock Performance
52-week high: $208.44
52-week low: $95.58
Price action over last quarter: Up 27.80%
Company Profile
Charles River Laboratories is a leading provider of drug discovery and development services. With roughly 50% of market share worldwide, the research model and services segment is the leading provider of animal models for laboratory testing. About half of the company's revenue comes from drug discovery and preclinical testing, and one fourth comes from the manufacturing support segment.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
